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OBJECTIVE: Isolated limb perfusion combined with melphalan is an accepted treatment for obtaining locoregional
control in advanced melanoma of the extremities and other malignant neoplasias restricted to the limb. This study
aims to examine the factors associated with toxicity caused by the regional method. We considered the technical
aspects of severe complications associated with the procedure in an attempt to diminish the patient morbidity that
occurs during the learning curve.
METHODS: We conducted a retrospective analysis of the records of patients who underwent perfusion at the AC
Camargo Hospital in Sa˜o Paulo, Brazil between January 2000 and January 2009. The Wieberdink scale was applied to
classify local toxicity and its relation to clinical and laboratory variables.
RESULTS: Fifty-eight perfusions were performed in 55 patients. Most patients (86.2%) presented a toxicity level
between I and III. Grade V toxicity was seen in five cases (8.6%), four of which occurred in the first 2 years. Creatine
phosphokinase, an important predictive factor for toxicity, had an average value of 231.8 for toxicity grades I-III and
1286.2 for toxicity grades IV-V (p= 0.001). There was a relationship between the melphalan dose and toxicity, which
was 77 mg (25 to 130 mg) for toxicity grades I-II and 93.5 mg (45 to 120 mg) for toxicity grades IV-V (p= 0.0204).
CONCLUSION: It is possible to prevent the toxicity associated with melphalan by adjusting the dose according to the
patient’s body weight (especially for women and obese patients) and the creatine phosphokinase values in the
postoperative period.
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INTRODUCTION
Isolated limb perfusion (ILP) is an alternative method that
allows the regional administration of chemotherapy to
patients with advanced melanoma and other malignant
neoplasias restricted to the limb. ILP combined with
melphalan is an accepted treatment modality for obtaining
locoregional control in advanced melanoma of the extre-
mities (1).
The use of regional perfusion combined with the
administration of cytostatic drugs was suggested by Klopp
et al. (2) in 1950 in an attempt to avoid the systemic toxic
effects of increasing doses of nitrogen mustard. Briefly, a
cannula was placed into the major artery supplying the
tumor site, and the drug was then administered. In 1956,
Luck reported that melphalan was an effective agent when
combined with ILP to treat melanoma in mice (3). Three
years later, Creech et al. (4) first treated a patient using the
independent vascular blood circulation of the affected limb
isolated from the systemic circulation with an extracorpor-
eal machine using an oxygenator and high doses of
melphalan. In 1967, the technical basis of ILP with
hyperthermia was established, and Cavaliere et al. (5)
described the selective susceptibility of cancer cells at high
temperatures.
The mortality and regional toxicity rates associated with
ILP surgery are considered low. Systemic leakage of the
cytostatic drug(s) is negligible (6,7), although severe toxicity
can occur (8-10).
Despite the common assumption of a relationship
between side effects and drug response, the relationship
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between toxicity and the response to ILP has never been
shown (11). Considering that these patients have advanced
disease, all efforts should be made to avoid negatively
affecting their quality of life. Thus, severe treatment-related
side effects must be avoided at all costs, as increased toxicity
and its associated side effects are not associated with better
treatment responses.
Many factors have been shown to affect toxicity, such as
limb temperature above 40oC, female gender, intense
exchange of blood gases in the perfusion circuit, proximal
iliac perfusion, and melphalan peak concentration (9,12-14).
It is possible to minimize acute regional toxicity by
carefully considering these factors. Increased consideration
of these factors should also decrease the incidence of long-
term morbidity, especially ankle stiffness, limb malfunction,
and muscle atrophy. A relationship between the severity of
acute regional tissue reactions and later morbidity has been
recognized (15).
Pasin et al. (16) described the treatment responses in 44
perfusions categorized as complete (43.2%), partial (36.4%),
and unresponsive (20.4%). Although toxicity details were
not described in the study, it was reportedly limited to
slight erythema and edema. In one case, amputation was
required because of the treatment.
In this study, we analyzed the risk factors associated with
limb toxicity. Cases of amputation following ILP are seldom
described in the literature. Here, we consider the technical
aspects related to severe complications associated with ILP
in an attempt to diminish the patient morbidity that has
been observed during the ILP learning curve typically
observed by health teams.
PATIENTS AND METHODS
A retrospective analysis was performed based on the
medical records of 55 patients treated with the ILP
technique at the A. C. Camargo Hospital in Sa˜o Paulo,
Brazil between January 2000 and January 2009. Cases for
which no medical records were available were excluded.
The casuistic included 46 patients with melanoma, four
cases of skin squamous cell carcinomas, and five cases of
soft tissue sarcomas. In the sarcoma group, two were
classified as clear cell sarcomas, two as epithelioid tumors,
and one as ganglioneuroblastoma. Almost all cases of
melanoma were Stage IIIB or IIIC, and only one patient
was in Stage IV.
Our perfusion technique has been described in detail
elsewhere (17). Briefly, melphalan (Alkeran GlaxoSmith-
Kline, Rio de Janeiro, Brazil) was used as a single agent in
dosages of 10 and 13 mg/L of limb volume (previously
measured) for the leg and arm, respectively. After verifying
that no significant leakage had occurred and the intramus-
cular temperature was near 38.5 C˚, the drug was infused. The
infusion lasted 15 minutes, and the target temperature of 40 C˚
was maintained for one hour, including the infusion period.
After that, the limb was washed with at least 2 liters of Ringer
solution, the cannulas were removed, and the vessels were
repaired.
Data related to the patients’ age, sex, type of disease,
stage, affected limb, dose of melphalan received, limb
temperature, blood gases, systemic and limb hemoglobin
and hematocrit during the procedure, duration of post-
operative hospitalization, degree of toxicity, creatine phos-
phokinase (CPK) level, day of the highest CPK level and
response were tabulated in a spreadsheet and used as the
nominal measurement level. The tumor’s response to
treatment and the procedure-related toxicity were analyzed
according to the clinical and laboratory data.
Tissue toxic reactions after the ILP procedure and
melphalan administration were classified according to
Wieberdink’s scale (Table 1) (18).
Tumor response was assessed according to the World
Health Organization criteria: complete response (CR) corre-
sponds to total regression of all injuries; partial response (PR)
corresponds to at least a 50% reduction of the tumor volume;
no response (NR) corresponds to a tumor volume reduction
of less than 50% or disease progression (19).
The Mann-Whitney test was used to compare the mean
values of several numerical variables according to the
toxicity grade. Toxicity-rate comparisons based on catego-
rical variables were conducted using Fisher’s exact test and
the chi-squared test. The significance level was set to 5% in
all statistical tests.
All patients signed the informed consent form, and the
local Ethics Committee approved the study.
RESULTS
Fifty-eight perfusions were performed with isolated
limb hyperthermia and chemotherapy in 55 patients; three
patients underwent the procedure twice. Population char-
acteristics are shown in Table 2.
Toxicity of the method
Most patients progressed with a degree of toxicity
ranging from I to III; however, toxicity grades IV and V
were also present (Table 3). The learning curve associated
with the procedure was included in the study period.
Table 1 - Acute Regional Toxicity Grading System,
according to Wieberdink et al. (18).
Grade Reaction
I No reaction
II Slight erythema and/or edema
III Considerable erythema and/or edema with some blistering;
slightly disturbed motility permissible
IV Extensive epidermolysis and/or obvious damage to the deep
tissues, causing definite functional disturbances;
threatened or manifest compartmental syndrome
V Reaction that may necessitate amputation
Table 2 - Characteristics of the population: Diagnosis and
stage.
Characteristic Number (%)
Diagnoses
Melanoma
Sarcoma
Squamous cell carcinoma
46 (84)
5 (9)
4 (7)
Stage (melanoma)
IIIC
IIIB
IV
30 (64)
16 (34)
1 (2)
Age (years)
Median: 62; range: 23-84Limb
Upper
Lower
8 (14.5)
47 (85.5)
Isolated Limb Perfusion and Toxicity
Duprat JP et al.
CLINICS 2012;67(3):237-241
238
The relationship between gender and toxicity was
analyzed. The patients were divided in two groups, a grade
I-III group and a grade IV-V group. Although four of the
five patients with grade V toxicity were female and 10 of the
12 patients with toxicity $ grade III were female, the
difference between genders was not statically significant
(Table 4).
Serum creatine phosphokinase (CPK) is an important
parameter for assessing toxicity in these patients. The
maximum median CPK values were 435, 324, 259, 206, and
285 (from the first postoperative day to the fifth day
postprocedure). The relationship between toxicity and
clinical and laboratory parameters is shown in Tables 5 and 6.
There was a clear relationship between toxicity and CPK
values greater than 1,000. A total of 19.1% of patients with
toxicity grades I-III had CPK values greater than 1,000,
compared with 62.5% of patients with grades IV and V
toxicity (p= 0.02).
There was no significant relationship between toxicity
and other parameters, such as stage, systemic pO2, pCO2,
pH, base excess, bicarbonate, hemoglobin, hematocrit,
diagnosis (melanoma vs. nonmelanoma), and limb (upper
vs. lower). There were 50 cases of lower limb tumors, of
which 86% had grade I-III toxicity. This value was not
significantly different compared to the toxicity observed in
cases in which the upper limb was affected (87.5%).
There was a relationship between the melphalan dose and
CPK values (highest and mean values, p= 0.002 and 0.003;
Table 6) and systemic pH and CPK (highest and mean
values, p= 0.001 and 0.001).
Patients with melanoma were hospitalized for an average
of 9 days after surgery (range: 4 to 52 days). Nonmelanoma
patients were hospitalized for an average of 7 days (range: 5
to 17 days).
DISCUSSION
Patients who are eligible for ILP had advanced-stage
cancer. Although the objective of any medical treatment is to
cure the patient, in many cases, the only benefit is
maintaining a good quality of life. Thus, avoiding or
limiting the side effects associated with ILP is imperative
for preserving the patient’s limb and minimizing patient
suffering. In this study, we showed that it is possible to
prevent the toxicity associated with high dosages of
melphalan by adjusting the dose according to the patient’s
body weight (especially in women and obese patients),
muscle temperature, and blood gas (pCO2 and pH) levels
and by considering the hematocrit and CPK values in the
postoperative period.
Klaase analyzed 425 patients and described the following
risk factors associated with toxicity (9):
a) Tissue temperature: In the group that achieved limb
temperatures #37.9 C˚, 10% had a toxicity grade $ III. In the
group that achieved limb temperatures $40 C˚, 36% had a
toxicity grade $ grade III, with a steep increase in toxicity at
temperatures above 41 C˚.
In most cases in the present study, the temperature was
maintained at approximately 39 to 40 C˚. Furthermore, our
group of patients was smaller than Klaase9s group. In our
study, limb temperatures were not significantly different
between grades I-III and grades IV and V toxicity groups,
most likely because of the smaller sample size. In the grades
I-III toxicity group, the median temperature achieved was
39 C˚ (range: 36 to 39.5) and in the grades IV and V group,
the median temperature achieved was 38 C˚ (range: 38 to
38.5 C˚); p= 0.371.
b) Gender: The muscle + skin/fat tissue ratio was
different between genders. Because fat tissue has less
vascularization than muscle, if the same dose is adminis-
tered to a limb with a greater proportion of fat tissue, more
of the drug will enter the muscle tissue, which results in
higher toxicity. This may explain why the toxicity is
different between genders. The ratio of patients with toxicity
greater than grade II was 0.18 female:0.07 male. Recently,
we corrected the dose according to ideal weight, which
reduced side effects. In the present study, four of the five
patients with grade V toxicity were female and 10 of the 12
patients with $ grade III toxicity were female.
The pH and hypoxia levels have been also been reported to
affect the toxicity associated with ILP. By damaging endothe-
lial cells, hypoxia increases the drug uptake and impairs the
repairing of normal tissue. The association between hypoxia
and acidic pH increases toxicity due to increased drug uptake
and reduced melphalan hydrolysis (20).
Hematocrit values below 20% in the perfusate also
increase the occurrence of toxicity. This phenomenon
occurred in three out of six cases of grade IV toxicity (21).
Animal studies have tested and confirmed that low
hematocrit increases grades III and IV toxicity (22).
The side effects of melphalan are related to the amount of
the drug that is administered. Pace et al. (23) compared
three groups of patients: Group A was submitted to mild
hyperthermia, melphalan (10 mg/l) and D-actinomycin;
Table 3 - Toxicity.
Toxicity Number of patients (percentage)
I 1 (1.7)
II 45 (77.6)
III 4 (6.9)
IV 3 (5.2)
V 5 (8.6)
Total 58 (100)
Grade I-III 50 (86.2)
Grade IV-V 8 (13.8)
Table 4 - Toxicity and gender; p= 0.139.
Toxicity Total
Grade I-III
n (%)
Grade IV-V
n (%)
Gender Female 29 (58) 7 (87.5) 36 (62.1)
Male 21 (42) 1 (12.5) 22 (37.9)
Total 50 (100) 8 (100) 58 (100)
Table 5 - Relationship between toxicity and clinical
parameters (categorical variables).
Toxicity Total p-value
Grade I-III
n (%)
Grade IV-V
n (%)
Limb Lower 43 (86) 7 (14) 50 (100) p= 0.417
Upper 7 (87.5) 1 (12.5) 8 (100)
Response No response 8 (88.9) 1 (11.1) 9 (100) p= 0.363
Partial/complete 42 (95.5) 2 (4.5) 44 (100)
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Group B was submitted to true hyperthermia (40 to 41.8 C˚);
and Group C was submitted to true hyperthermia and an
additional bolus of 5 mg/l of melphalan. Group C pre-
sented an increase in grade III toxicity. The authors
observed 1.6% mortality (3 cases) in Groups B and C.
Thompson et al. (12,24) analyzed the use of a high-
performance liquid chromatography (HPLC) system to
measure the drug dosage in the perfusate during surgery
and found that the peak dosage of melphalan influenced
toxicity levels. Using an indocyanine green dilution method,
it was possible to observe that perfusate volume is quite
variable. Consequently, the peaks of dose, toxicity and
effects are also variable (12,24). In the present study,
patients with toxicity # grade III had a mean melphalan
dose of 77 mg vs. 93.5 mg in the group with toxicity grades
IV and V; however, the difference was not statistically
significant (p= 0.204), possibly because of our small sample.
Muscle damage can occur as a result of ILP, and an
important parameter for muscle damage is the peak value of
creatinine phosphokinase (CPK). Lai et al. (25) were the first
authors to analyze the CPK value at the day of its peak.
They found that if CPK remained normal or peaked
between the second and fourth days, the toxicity was mild.
However, if peak values were greater than 1,000 after the
fifth day, the toxicity was high. Vrouenraets et al. showed
that if CPK remains normal or shows an early peak (before
the 4th day), the chances of severe toxicity are lower. A ‘‘late
peak’’ CPK pattern (i.e., a peak that occurs after the 5th day
and is greater than 1,000 IU/L) indicates a higher prob-
ability of regional toxicity. Seven out of 15 limbs had severe
toxicity with CPK values higher than 1,000 IU/L on the 2nd
to 5th days after ILP. Other studies have confirmed this
finding (25-27).
Vrouenraets et al. also tested CPK and other blood
parameters (27). These authors analyzed lactate dehydro-
genase (LDH), aspartate aminotransferase (ASAT), and
white blood cell counts (WBC). A strong correlation
between toxicity and LDH peak was observed, but it
occurred later than the CPK peak. The LDH peak occurred
4.7 days after ILP, which was 2.9 days after the CPK peak.
The differences in ASAT levels did not reach statistical
significance. WBCs increased between days 3 and 8 in
grades IV and V toxicity compared with grades II and III. In
the present study, there was a clear correlation between
CPK levels (mean, highest level and number of cases with
doses over 1,000 units) and toxicity (p= 0.001, 0.001, and
0.02, respectively).
Boesh et al. (21) showed that low hematocrit (below 20%)
of the perfusate increases the occurrence of toxicity. This
phenomenon occurred in three out of six Grade IV toxicity
cases. We did not investigate this occurrence in our study.
Cause of Grade V toxicity
It is very important to explain the possible causes of
grade V toxicity to minimize suffering in patients with
advanced disease. Unfortunately, these causes have not
been reported or investigated. In this study, we aimed to
better understand the causes associated with high toxicity
for each patient.
A 51-year-old man received two perfusions. Initially, he
demonstrated a complete response and grade II toxicity, but
he had a recurrence after 4 months. He received systemic
chemotherapy with dacarbazine (DTIC), and his disease
was stable for almost a year; after that, however, the disease
in the affected limb worsened. A new perfusion was
completed; after 1 week, he developed phlegmasia cerulea
dolens and underwent amputation. It has been established
that second perfusions increase toxicity from 21 to 58% (28).
Another patient was a 57-year-old obese female. For this
patient, the calculated and administered dose of melphalan
was 120 mg. At that time it was the usual calculated dose
but recently the concept of correcting the dose by ideal
weight was introduced. Another problem associated with
this case was that the temperature probe should have been
placed intramuscularly, but was likely placed in the
subcutaneous tissue. While the registered temperature was
38 C˚, the actual temperature inside the muscle was probably
higher.
Four cases of grade V toxicity occurred in our first two
years of using ILP, indicating that we were at the middle of
the learning curve. The fifth case occurred in 2005 (our fifth
year of using ILP), and we have had no cases of grade V or
IV toxicity in the subsequent six years.
In conclusion, the prevention of regional and systemic
toxicity is essential for improving the quality of life of
patients with advanced disease. It is possible to prevent
the toxicity associated with high doses of melphalan by
adjusting the dose according to the patient’s body weight
(especially in women and obese patients), muscle tempera-
ture, blood gas (pCO2 and pH) levels, and by considering
the hematocrit and CPK values in the postoperative period.
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